Logo

Novoheart Collaborates with AstraZeneca to Develop World's First Heart-in-a-Jar Model of Heart Failure

Share this

Novoheart Collaborates with AstraZeneca to Develop World's First Heart-in-a-Jar Model of Heart Failure

Shots:

  • The collaboration initially focuses on developing in vitro- functional model of heart failure with HFpEF utilizing Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology which reproduces key phenotypic characteristics of HFpEF
  • The focus of the collaboration is to combine Novoheart’s hvCOC model with AstraZeneca’s expertise in heart failure to build the gap between in vivo animal models and clinical studies- thus accelerating the discovery process by providing human-specific preclinical data
  • Human heart-in-a-jar is the only human-engineered heart tissue available in the market which fabricated with specific cellular & matrix compositions and iPSCs- allowing control over patient’s physical and mechanical properties to mimic observation in HFpEF heart

Click here to­ read full press release/ article 

Ref: GlobeNewswire | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions